oxazolidin-2-one has been researched along with niacin in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 7 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fisher, T; Hubbard, B; Kling, J; Li, H; Pagler, T; Sparrow, CP; Taggart, AK; Tall, AR; Yvan-Charvet, L | 1 |
| Ballantyne, CM; Virani, SS | 1 |
| Einecke, D | 1 |
| Arsenault, BJ; Brodeur, MR; Rhainds, D; Tardif, JC | 1 |
| Francis, DP; Keene, D; Price, C; Shun-Shin, MJ | 1 |
| McCullough, PA; Shin, HJ | 1 |
| Ashraf, TB; Ballantyne, CM; Cressman, MD; Gill, GG; Hunter, JA; Johnson-Levonas, AO; Kher, U; Mitchel, YB; Shah, S | 1 |
3 review(s) available for oxazolidin-2-one and niacin
| Article | Year |
|---|---|
An update on the clinical development of dalcetrapib (RO4607381), a cholesteryl ester transfer protein modulator that increases HDL cholesterol levels.
Topics: Amides; Animals; Anticholesteremic Agents; Cardiovascular Diseases; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Clinical Trials, Phase II as Topic; Drug Therapy, Combination; Esters; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Metabolic Syndrome; Niacin; Oxazolidinones; Plaque, Atherosclerotic; Recurrence; Sulfhydryl Compounds | 2012 |
Effect on cardiovascular risk of high density lipoprotein targeted drug treatments niacin, fibrates, and CETP inhibitors: meta-analysis of randomised controlled trials including 117,411 patients.
Topics: Amides; Anticholesteremic Agents; Cholesterol Ester Transfer Proteins; Coronary Disease; Esters; Fibric Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipoproteins, HDL; Myocardial Infarction; Niacin; Oxazolidinones; Quinolines; Randomized Controlled Trials as Topic; Stroke; Sulfhydryl Compounds | 2014 |
Focus on lipids: high-density lipoprotein cholesterol and its associated lipoproteins in cardiac and renal disease.
Topics: Amides; Apolipoprotein A-I; Benzodiazepines; Black or African American; Cholesterol Ester Transfer Proteins; Cholesterol Esters; Cholesterol, HDL; Cholesterol, LDL; Cohort Studies; Esters; Heart Diseases; Humans; Hyperlipoproteinemias; Kidney Diseases; Liver; Niacin; Observational Studies as Topic; Oxazolidinones; Prospective Studies; Quinolines; Randomized Controlled Trials as Topic; Risk; Sulfhydryl Compounds; Triglycerides; White People | 2014 |
1 trial(s) available for oxazolidin-2-one and niacin
| Article | Year |
|---|---|
Lipid-Modifying Efficacy and Tolerability of Anacetrapib Added to Ongoing Statin Therapy in Patients with Hypercholesterolemia or Low High-Density Lipoprotein Cholesterol.
Topics: Aged; Anticholesteremic Agents; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Cholesterol, LDL; Double-Blind Method; Drug Therapy, Combination; Dyslipidemias; Ezetimibe; Female; Fibric Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Niacin; Oxazolidinones; Treatment Outcome | 2017 |
3 other study(ies) available for oxazolidin-2-one and niacin
| Article | Year |
|---|---|
Cholesterol efflux potential and antiinflammatory properties of high-density lipoprotein after treatment with niacin or anacetrapib.
Topics: Animals; Anti-Inflammatory Agents; ATP Binding Cassette Transporter 1; ATP Binding Cassette Transporter, Subfamily G, Member 1; ATP-Binding Cassette Transporters; Cells, Cultured; Cholesterol; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Clinical Trials as Topic; Dyslipidemias; Foam Cells; Humans; Hypolipidemic Agents; Inflammation; Inflammation Mediators; Lipoproteins; Macrophages; Mice; Mice, Knockout; Niacin; Oxazolidinones; Time Factors; Toll-Like Receptor 4; Treatment Outcome | 2010 |
Update on therapies targeting HDL: the mystery continues.
Topics: Animals; Cholesterol Ester Transfer Proteins; Cholesterol, LDL; Coronary Disease; Early Termination of Clinical Trials; Humans; Lipoproteins, HDL; Niacin; Oxazolidinones; Randomized Controlled Trials as Topic | 2011 |
[Secondary coronary heart disease prevention. Will CEPT inhibitors be the next breakthrough?].
Topics: Acute Coronary Syndrome; Amides; Benzodiazepines; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Delayed-Action Preparations; Drug Therapy, Combination; Drugs, Investigational; Esters; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Niacin; Oxazolidinones; Randomized Controlled Trials as Topic; Sulfhydryl Compounds | 2011 |